摘要
目的探讨胃复春片联合兰索拉唑治疗慢性萎缩性胃炎的临床疗效及对血清IL-1β、sIL-2R和MTL水平的影响。方法选取2016年9月~2018年2月到我院消化内科接受治疗的慢性萎缩性胃炎患者180例作为研究对象,患者按照入院前后治疗顺序分为对照组与观察组,各组90例。对照组给予口服兰索拉唑片治疗,观察组给予口服胃复春片联合兰索拉唑片治疗,比较两组临床疗效、临床症状评分、不同症状情况、血清学指标、病理分级及胃底黏膜幽门腺黏膜萎缩及肠上皮化生的变化。结果观察组总有效率优于对照组(P<0.05);治疗后,观察组胃脘疼痛、胃中嘈杂、嗳气泛酸与口苦口干评分明显下降,且低于对照组(P<0.05);观察组治疗后不同病症发生率小于对照组,且观察组不同病症改善水平高于对照组(P<0.05);治疗后,两组血清IL-1β、SIL-2R、GAS、MTL水平显著下降,G-17水平升高;观察组血清学指标改善程度优于对照组(P<0.05);观察组治疗后内镜分级优于对照组(P<0.05);治疗后观察组腺体萎缩评分与肠上皮化生评分低于对照组(P<0.05),治疗后观察组腺体萎缩减少低于对照组(P<0.05),两组肠上皮化生变化比较差异无统计学意义(P>0.05)。结论胃复春片联合兰索拉唑治疗慢性萎缩性胃炎临床疗效显著,可优化临床症状,明显改善血清IL-1β、SIL-2R、GAS、MTL水平与G-17水平,胃黏膜萎缩与肠上皮化生明显转归,具有临床价值,可在临床推广应用。
Objective To investigate the clinical efficacy of Weifuchun tablet combined with lansoprazole on serum IL-1β, sIL-2 R and MTL levels in the treatment of chronic atrophic gastritis. Methods 180 patients with chronic atrophic gastritis treated in the Gastroenterology Department of our hospital from September 2016 to February 2018 were selected and divided into two groups according to the admission order, each with 90 cases. The control group received lansoprazole. Based on this, the observation group received the Weifuchun tablet. The clinical efficacy, clinical symptom scores, pathological grades, different pathological conditions, serological indicators, gastric atrophy and intestinal metaplasia were compared between the two groups. Results The total effective rate of the observation group was higher than that of the control group(97.78% vs 88.88%, P<0.05). A significant decrease showed in the scores of epigastric pain, noisiness in the stomach, beryllium pantothenic acid and oral dry mouth in both groups(P<0.05). The incidence rate of different complications in the observation group was lower than that in the control group, and the amelioration of various symptoms was more significant in the observation group than in the control group(P<0.05). The endoscopic grading of the observation group was significantly better than that of the control group(P<0.05). The levels of serum IL-1β, SIL-2 R, GAS, and MTL were significantly decreased in both groups, moreover, the G-17 levels were significantly increased, and both changes were more obvious in the observation group than in the control group(P<0.05). The scores of gastric atrophy and intestinal metaplasia in the observation group were lower than those of the control group after treatment(P<0.05). The gland atrophy of the observation group was lower than that of the control group(P<0.05), while no difference was found in the intestinal metaplasia(P>0.05).Conclusion Weifuchun tablet combined with lansoprazole can effectively ameliorate the clinical symptoms, serum IL-1β, sIL-2 R, GAS, MTL and G-17 levels, along with the gastric atrophy and intestinal metaplasia, regulate gastrointestinal hormone levels for patients with chronic atrophic gastritis, which is worth promoting.
作者
李加虎
张德乐
赵剑峰
沈洪涛
王世恒
LI Jiahu;ZHANG Dele;ZHAO Jianfeng;SHEN Hongtao;WANG Shiheng(Department of Gastroenterology, Jiangning Hospital Affiliated to Nanjing Medical University,Nanjing 211100,China;Faculty of Pharmaceutical Sciences, Jiangning Hospital Affiliated to Nanjing Medical University,Nanjing 211100,China)
出处
《西部医学》
2019年第7期1043-1047,共5页
Medical Journal of West China
基金
江苏省自然科学基金(BK20141436)
关键词
胃复春片
兰索拉唑
慢性萎缩性胃炎
血清学指标
Weifuchun tablet
Lansoprazole
Chronic atrophic gastritis
Serological index
